Adjuvance Technologies Celebrates $20M Investment and New Office

Adjuvance Technologies (www.adjuvancetechnologies.com) recently received a $20 million Series A investment from Morningside Venture Investments Limited. The funds from the investment will be deployed to advance their first product through a proof-of-concept clinical trial. To celebrate, the Adjuvance Technologies team and representatives from the Lincoln Chamber of Commerce gathered on January 30 in the company’s new office at 1225 L St., STE 600, for a ribbon-cutting ceremony.

“We are pleased to receive this investment from Morningside,” said Tyler Martin, MD, chairman and CEO of Adjuvance. “They are a top tier life science venture investor, providing important validation of our technology. More importantly, together we have strategic alignment for building our business, and getting innovative vaccines to the people who need them.”

Lisa Sypal, Adjuvance Technologies’ director of investor relations, said the company is also appreciative of the local support they’ve received as well: “Our partnership with Nebraska Innovation Campus and the early support provided by groups like the Nebraska Department of Economic Development, Invest Nebraska, and local angel investors have been a key component in our ability to advance our mission.”

Adjuvance Technologies, Inc. is a privately held biopharmaceutical company focused on empowering health through fundamental breakthroughs in vaccine adjuvant design and manufacturing. Its lead adjuvant, TQL1055, is in pre-clinical development for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy. More information is available at www.adjuvancetechnologies.com. Further questions can be directed to Lisa at (402) 817-5050 Ext. 1116 / lsypal@adjuvancetechnologies.com.